The Immunology-Immunopathology-Immunotherapy (i3) laboratory, created in 2009, is dedicated to translational systems immunology. Its heuristic objective is to contribute to the advancement of fundamental knowledge in immunology and its applied objective is to develop innovative immunotherapies against autoimmune & inflammatory diseases and allergy. Thus, i3 uses systems biology approaches to analyze the complexity of cellular interactions and regulations during immune responses and in therapeutics. i3 masters complex data analysis in cytomics, genetics, microbial metagenomics, transcriptomics and proteomics, and has a particular expertise in the analysis of the T cell TCR repertoire. i3 brings together immunologists, clinicians, bioinformaticians, mathematicians, computer scientists and statisticians who bring the multidisciplinary skills necessary to its ambition.<\/p>\n
<\/p>\n
Piti\u00e9-Salp\u00eatri\u00e8re Hospital
\nINSERM
\nSorbonne University<\/p>\n
CERVI building, 2nd & 4th floors,
\n47- 83 boulevard de l’h\u00f4pital 751013 Paris<\/p>\n
<\/p>\n
https:\/\/www.i3-immuno.fr<\/a><\/p>\n <\/p>\n Mail:<\/strong> i3.contact@transimmunom.org<\/a><\/p>\n Telephone:<\/strong> ‘+ 33(0)1.42.17.74.60 \/ 61<\/p>\n <\/p>\n INSERM and Sorbonne University<\/strong><\/p>\n <\/p>\n KLATZMANN David<\/strong><\/p>\n <\/p>\n <\/p>\n i3 is organized into three research themes: Clinical Immunology and Biotherapy (CiB) – Experimental Immunology and Biotherapy (EiB) – Integrative Immunology (i2)<\/p>\n The CiB theme aims to (i) explore the immune system in health and diseases and (ii) to develop and validate new immunotherapies in humans. This theme associates a clinical immunopathology component and a more fundamental component on Treg biology. CiB has a recognized expertise in translational immunology; it assembles researchers with scientific expertise in cellular immunology, and more specifically in Treg, and practicing medical doctors with hospital activities in the field of immunological diseases. Importantly, CiB’s work is part of large and well-funded structures and projects, including the i2B department, the Transimmunom LabEx, the RHU iMAP and the ERC TRiPoD.<\/p>\n <\/p>\n Research topics<\/strong><\/p>\n Clinical immunology & Biotherapy (CiB)<\/a><\/p>\n <\/p>\n Manager \/ Team Leader<\/strong><\/p>\n Mich\u00e8le Rozenzwajg<\/a><\/p>\n The Clinical Investigation Center in Biotherapy and Immunology has a unique expertise in translational research in immunology. The CIC-BTi offers support to investigators to perform clinical studies – from cognitive to therapeutic studies – in the fields of Biotherapies and Immunology.<\/p>\n <\/p>\n Research topics<\/strong><\/p>\n Experimental Immunology & Biotherapy : Clinical Investigation Center<\/a><\/p>\n <\/p>\n Manager \/ Team Leader<\/strong><\/p>\n David Klatzmann<\/p>\n The EiB themes are to (i) explore the immune system in physiological and pathological contexts and (ii) develop and validate new immunotherapies in mice. EiB has a recognized expertise in Treg biology and vaccination. Exploiting our experience in vaccines against infectious diseases23,24, we developed innovative immunotherapies with the specific aim of inducing immune tolerance and applying the strategies to treat AIDs and allergy. Two different approaches were developed: (i) one based on Treg-mediated therapies, (ii) the other based on antigen-specific tolerogenic vaccination, for which proof of concept was recently achieved (cf patents). Our research was mainly based on pre-clinical studies focusing on models of immune-mediated disorders, notably allergies and AIDs, and supports the “pre-clinical development” team of the Clinical Investigation Center in Biotherapy and Immunology (CIC-BTi) located at Piti\u00e9-Salp\u00eatri\u00e8re Hospital.<\/p>\n <\/p>\n Research topics<\/strong><\/p>\n Experimental immunology & Biotherapy<\/a><\/p>\n <\/p>\n Manager \/ Team Leader<\/strong><\/p>\n Bertrand Bellier<\/a><\/p>\n i2 expertise is in developing systems immunology approaches to study T cell differentiation and dynamics in physiological and pathological situations relying on statistical and dynamic computer modelling. Integration of multi-scale and multi-level data (flow cytometry, transcriptome, proteome, microbiome & repertoire) allows modelling the dynamics and repertoire diversity of lymphocyte populations as well as analyzing their gene expression.<\/p>\n <\/p>\n Research topics<\/strong><\/p>\nContact<\/h2>\n
Guardianship<\/h2>\n
Director \/ Head of structure<\/h2>\n
Research units<\/h2>\n
\nClinical immunology & Biotherapy (CiB)<\/h3>\n
\nExperimental Immunology & Biotherapy : Clinical Investigation Center<\/h3>\n
\nExperimental immunology & Biotherapy<\/h3>\n
\nIntegrative Immunology<\/h3>\n